comprehensive -WSS

comprehensive

author：entertainment 2025-08-12 06:44:35 - browse：1827

Editor’s note: A recording of the event is embedded below.

Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. market over the past year. What has that meant for insurance coverage and the way drugmakers are marketing these medicines? Join leading experts to discuss the impact on the industry and patients.

Sponsor introduction

Thomas Newcomer, vice president and head of U.S. market access, Samsung Bioepis (sponsor)

Featured speakers

Chris M. Brown, president, McAteer
Michael Gonzales, independent health care consultant, Michael Gonzales, LLC; former national and regional account director, AbbVie
Fran Gregory, MBA, PharmD, vice president of emerging therapies, Cardinal Health
Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)

WSS

Kaiser Permanente unions announce official strike date

Digital health: a case of mistaken identity

Kaiser Permanente unions announce official strike date

For longer

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Bird flu surveillance in wastewater gets boost from consortium

leisure time

comprehensive

Sponsor introduction

Featured speakers

Sponsored By

focus

Bright Health sells Medicare Advantage business to Molina

Investigation reveals sickle cell patients pressured into sterilizations

How to save PrEP access — and even expand it

Fentanyl is making it harder to start addiction treatment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Mindstrong's demise and the future of mental health care

United colonoscopy coverage change 'may cost lives,' doctors say

Researchers use wearables data and AI to predict preterm birth risk

As demand for Covid shots wanes, Moderna seeks its next success

Liver decline slowed by off

hotspot

Menendez indictment could see pharma lose a key ally

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Scrutiny of post

Making the case for fair compensation in clinical trials

For longer

After a drawn out lobbying fight, ARPA

focus

leisure time

knowledge

explore